A Global Bio Company that Leads the Bio Industry
GwangPyo Ko, Sc.D.
GwangPyo began his career as a microbiologist, working in research for a number of years before finding a Kobiolabs. He has published more than 100 papers and patents on health and food environment such as microbiome. Since 2011, he has been a director of Center for Human and Environmental Microbiome(Seoul National University) and also a PI and board member of International Human Microbiome Consortium. Prior to joining Seoul National University as a professor of Environmental Health Microbiology, he conducted post-doctoral work from University of North Carolina Chapel Hill and served as a assistant professor at Dept. of Environmental Health from University of Texas Health Science Center afterwards. He earned a M.S. and Sc.D. in Environmental Health from Harvard University.
Cheolwon joined Kobiolabs as CEO in Feb 2018. He has more than 20 years of extensive experiences from drug discovery & development to business development in a pharmaceutical industry. He most recently served as Head of Portfolio & BD at Alvogen Asia Pacific and Head of R&D at Alvogen Korea. Prior to that, he worked at LG Life Sciences and CJ Cheiljedang. Cheolwon has his B.A. in Pharmacy and his M.S. in Medicinal Chemistry from Seoul National University.
Tae-Wook Nam, Ph.D.
Chief Technology Officer
Tae-Wook has been Chief Technology Officer since 2017 overseeing in-house research and development. Prior to his current appointment, he served as a Director of NGS Service Division at Macrogen, Inc. He was responsible for the entire laboratory activities of Macrogen's NGS and biochip services aimed for genome research. He holds a doctorate and master’s degree in microbiology from Seoul National University
Head of Clinical Development
Yurn-Su Song is in charge of Clinical Development of Kobiolabs pipeline with the responsibility in clinical operation and regulatory affairs. She has over 23 years of pharma industry experience in multinational pharma companies such as Eli Lilly, Pfizer, and Boehringer Ingelheim, the majority of which has been gained in clinical operation of new drugs. She most recently served as a senior director at Archigen Biotech in supply chain and vendor management and prior to that she had a role of leading Clinical Development at Boehringer Ingelheim Korea. She has a B.A. in pharmacy from Ewha Women’s University.
Head of Pharmaceutical Development
Prior to joining Kobiolabs as Head of Pharmaceutical Development, he was a director of business development at Alvogen Korea where he led portfolio management, new product launch and various domestic and overseas partnering. He has 20 years of pharmaceutical industry experience in R&D and BD field with various companies from R&D driven big Korean conglomerates (LG Life Science & CJ Cheiljedang) to multinational company (Alvogen). He earned a M.S. in Medicinal Chemistry from Seoul National University.
Yong Won Shin
Head of CMC Department
Yong Won Shin joined Kobiolabs as Head of CMC Department. He has 18 years of experience in the biotechnology industry, with a focus in bioprocess development, manufacturing support and project leadership. Prior to joining Kobiolabs, he led CMC team at GC Pharma and was responsible for Antibody engineering, Downstream Process Development, Project Management and CMC management. He holds a doctorate in Medical Science from Kyunghee University and a master’s degree in Genetic Engineering from Kyungpook National University.